Read More About Medicines in Development for Heart Disease & Stroke

Every 39 seconds an American dies from cardiovascular disease, and more than 83 million Americans have at least one type of the disease, the American Heart Association (AHA) reports. However, death rates from heart disease and stroke are falling, thanks in large part to new medicines. Advances in medicine have helped cut deaths from heart disease by one third between 2001 and 2011, according to the Centers for Disease Control and Prevention (CDC).

Read More About Medicines in Development for Diabetes

Subscribe buttonAmerica’s biopharmaceutical research companies currently are developing 180 innovative new medicines to help the nearly 400 million people who have diabetes worldwide.

Read More About Medicines in Development for Chronic Obstructive Pulmonary Disease (COPD)

America’s biopharmaceutical research companies are working on 54 medicines to treat chronic obstructive pulmonary disease (COPD), according to a report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA). These exciting therapies are in late-stage development, meaning they are either in clinical trials or awaiting review by the Food and Drug Administration (FDA).

Read More About Medicines in Development for Biologics

America’s biopharmaceutical research companies are using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases, according to a new report from PhRMA. The medicines and vaccines – all in human clinical trials or under review the U.S. Food and Drug Administration (FDA) – include 338 monoclonal antibodies, 250 vaccines, 93 recombinant proteins, 60 cell therapies, 46 gene therapies and 30 antisense medicines.  

Medicines in Development for Older Americans

America’s biopharmaceutical research companies currently are developing 435 innovative new medicines to target 15 leading chronic conditions affecting the Medicare population.  These medicines in development – all either in clinical trials or under review by the Food and Drug Administration (FDA) – include 110 for diabetes, 62 for rheumatoid arthritis and osteoarthritis, 67 for Alzheimer’s disease, 61 for heart disease and 40 for chronic obstructive pulmonary disease (COPD), according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

Backgrounder: Selected Biologics in Development

Alzheimer’s disease affects more than 5 million Americans, according to the Alzheimer’s Association.  It also costs the U.S. health care system $200 billion a year. These sobering statistics are projected to get much worse as the 76 million American baby boomers age.A gene therapy for the treatment of Alzheimer's disease in clinical trials is designed to deliver nerve growth factor (NGF) to the brain.  NGF is a naturally occurring protein important for neuron survival.

Medicines in Development: Biologics 2013

Medicines in Development: Asthma

Read More About Medicines in Development for Asthma

America’s biopharmaceutical research companies are working on 74 medicines to treat asthma, according to a report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA). All of the medicines are either in clinical trials or awaiting review by the Food and Drug Administration (FDA).

Medicines in Development for Arthritis

America’s biopharmaceutical research companies are developing 92 innovative new medicines to help the millions of Americans affected by arthritis. These medicines in development – all either in clinical trials or under review by the U.S. Food and Drug Administration– include 55 for rheumatoid arthritis, 15 for musculoskeletal pain, 10 for osteoarthritis and 7 for psoriatic arthritis, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

Pages

Subscribe to RSS - Innovation